Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a U.S.-based biopharmaceutical company focused on therapies for serious rare and ultra-rare genetic diseases. Its portfolio combines approved medicines and clinical-stage programs across biologics, small molecules, AAV gene therapy, and nucleic acid-based candidates, with commercialization in North America, Europe, Latin America, Türkiye, Asia, and selected international markets.

−74,3 %

−85,4 %

+20,1 %

2.48

2.34

— Ultragenyx Pharmaceutical Inc.
%
Approved rare disease therapies75% Commercial medicines for genetically defined rare diseases such as XLH, TIO, MPS VII, LC-FAOD and HoFH.
AAV gene therapy candidates15% Gene therapy programs aimed at correcting the underlying cause of inherited metabolic and genetic disorders.
Biologics and antibody programs5% Protein and antibody-based therapies, including approved products and late-stage candidates.
Small molecule and nucleic acid programs5% Non-biologic pipeline assets designed for rare disease mechanisms and targeted genetic correction.

Ultragenyx sells primarily to patients with rare genetic diseases through specialty pharmacies, distributors, and...

  • Rare disease patientsprimary

    Patients with XLH, TIO, MPS VII, LC-FAOD, HoFH and other genetic disorders who use the therapies chronically.

  • Specialty pharmaciesprimary

    Dispense approved products and influence ordering patterns, inventory levels and patient access.

  • Commercial distributorssecondary

    Handle product distribution in smaller international markets where Ultragenyx does not sell directly.

  • Specialist physicians and treatment centersprimary

    Diagnose rare diseases, prescribe therapies, and manage long-term treatment protocols.

  • Payers and reimbursement authoritiesprimary

    Approve coverage and reimbursement, which strongly affects adoption in orphan drug markets.

Ultragenyx commercializes its products across North America, the European Union, the United Kingdom, Latin America,...

  • •Commercial presence spans North America, Europe, Latin America and Asia
  • •Own sales organization in major markets supports rare-disease commercialization
  • •Third-party distributors are used in smaller markets and can affect sell-through
  • •Europe is important for Evkeeza® commercialization outside the U.S.
  • •Geographic execution matters because orphan-drug access is highly local

Ultragenyx focuses on in-licensing promising rare-disease assets and retaining global commercialization rights where...

01
Advance multiple rare-disease programs in parallelmedium-term

Diversifies pipeline risk and creates several shots on goal in small markets.

02
Expand and defend commercial productsshort-term

Approved therapies fund the business and establish relationships with rare-disease specialists.

03
Preserve global commercialization rightslong-term

Owning ex-U.S. and U.S. rights where possible increases long-term value capture.

04
Leverage rare-disease development capabilitieslong-term

Patient identification, trial design and regulatory execution are key competitive advantages in orphan drugs.

Ultragenyx depends on successful commercialization of a small number of approved products and on clinical and...

critical

Manufacturing and single-source supply disruption

Drug substance and drug product for many products and candidates come from single-source suppliers.

Scope
Commercial products and gene therapy pipeline
Materiality
high
high

Small addressable patient populations

Rare-disease markets are inherently limited, so patient identification and penetration are critical to revenue.

Scope
Approved products and pipeline programs
Materiality
high
high

Clinical and regulatory failure

Pipeline value depends on successful trials, endpoints, and approvals in complex orphan indications.

Scope
UX701, UX143, DTX401 and other candidates
Materiality
high
high

Distributor and specialty pharmacy concentration

A considerable portion of sales flows through a small number of intermediaries, affecting sell-through and inventory.

Scope
Commercial product sales
Materiality
medium
high

Reimbursement and market access

Orphan drugs often require payer approval and favorable coverage to achieve broad uptake.

Scope
All approved therapies
Materiality
high
high

Dependence on Kyowa Kirin for Crysvita in major markets

The company relies on a partner for commercialization and supply in certain markets, including the U.S. and Canada.

Scope
Crysvita
Materiality
high
Revenue reserves
Can materially affect net product revenue and period-to-period comparability
Distributor and specialty pharmacy inventory patterns
Can create quarter-to-quarter volatility in product revenue
Liabilities for sales of future royalties
Affects balance sheet liabilities and interest-like expense recognition
Manufacturing and service contract obligations
Can affect operating liabilities and cash outflow timing
License and collaboration milestone payments
Creates uncertain future obligations and potential expense recognition

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

MANNKIND CORP

MNKD · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

EXELIXIS, INC.

EXEL · Biological Products, (No Diagnostic Substances)

: 29.4.2026